Advanced Magnetic Resonance Imaging for Early Diagnosis and Monitoring of Movement Disorders
- PMID: 39851446
- PMCID: PMC11763950
- DOI: 10.3390/brainsci15010079
Advanced Magnetic Resonance Imaging for Early Diagnosis and Monitoring of Movement Disorders
Abstract
Advanced magnetic resonance imaging (MRI) techniques are transforming the study of movement disorders by providing valuable insights into disease mechanisms. This narrative review presents a comprehensive overview of their applications in this field, offering an updated perspective on their potential for early diagnosis, disease monitoring, and therapeutic evaluation. Emerging MRI modalities such as neuromelanin-sensitive imaging, diffusion-weighted imaging, magnetization transfer imaging, and relaxometry provide sensitive biomarkers that can detect early microstructural degeneration, iron deposition, and connectivity disruptions in key regions like the substantia nigra. These techniques enable earlier and more accurate differentiation of movement disorders, including Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, Lewy body and frontotemporal dementia, Huntington's disease, and dystonia. Furthermore, MRI provides objective metrics for tracking disease progression and assessing therapeutic efficacy, making it an indispensable tool in clinical trials. Despite these advances, the absence of standardized protocols limits their integration into routine clinical practice. Addressing this gap and incorporating these techniques more systematically could bring the field closer to leveraging advanced MRI for personalized treatment strategies, ultimately improving outcomes for individuals with movement disorders.
Keywords: Parkinson’s disease; early diagnosis; magnetic resonance imaging; movement disorders; neurodegeneration biomarkers; neuroimaging.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.Front Neurol. 2020 Oct 15;11:572976. doi: 10.3389/fneur.2020.572976. eCollection 2020. Front Neurol. 2020. PMID: 33178113 Free PMC article. Review.
-
Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.Transl Neurodegener. 2017 Mar 28;6:8. doi: 10.1186/s40035-017-0076-6. eCollection 2017. Transl Neurodegener. 2017. PMID: 28360997 Free PMC article. Review.
-
Free-water imaging in Parkinson's disease and atypical parkinsonism.Brain. 2016 Feb;139(Pt 2):495-508. doi: 10.1093/brain/awv361. Epub 2015 Dec 24. Brain. 2016. PMID: 26705348 Free PMC article.
-
Magnetic resonance imaging of the substantia nigra in Parkinson's disease.Mov Disord. 2012 Jun;27(7):822-30. doi: 10.1002/mds.25015. Epub 2012 May 30. Mov Disord. 2012. PMID: 22649063 Review.
-
Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.Mov Disord. 2022 Jun;37(6):1245-1255. doi: 10.1002/mds.28988. Epub 2022 Mar 29. Mov Disord. 2022. PMID: 35347754
Cited by
-
Neural Correlates of Huntington's Disease Based on Electroencephalography (EEG): A Mechanistic Review and Discussion of Excitation and Inhibition (E/I) Imbalance.J Clin Med. 2025 Jul 15;14(14):5010. doi: 10.3390/jcm14145010. J Clin Med. 2025. PMID: 40725699 Free PMC article. Review.
-
MR-Guidance of Gene Therapy for Brain Diseases: Moving From Palliative Treatment to Cures.J Magn Reson Imaging. 2025 Apr 21:10.1002/jmri.29804. doi: 10.1002/jmri.29804. Online ahead of print. J Magn Reson Imaging. 2025. PMID: 40256948 Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous